MOS Prebiotic Potential in Older Adults
The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.
1 other identifier
interventional
40
1 country
1
Brief Summary
Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable healthy
Started Aug 2023
Longer than P75 for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 3, 2023
CompletedFirst Posted
Study publicly available on registry
July 11, 2023
CompletedStudy Start
First participant enrolled
August 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
ExpectedJanuary 9, 2026
January 1, 2026
7 months
July 3, 2023
January 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean daily rating of gastrointestinal symptoms
Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)
14 days
Study Arms (1)
Mannooligosaccharides
EXPERIMENTALMannooligosaccharides yeast extract
Interventions
15 g per day of mannooligosaccharide yeast extract.
Eligibility Criteria
You may qualify if:
- Adults 50-99 years of age.
- Able to provide written informed consent in English.
- Willingness to complete all study procedures
- Healthy or diagnoses with Parkinson's or multiple system atrophy
You may not qualify if:
- Yeast allergy.
- Self-reported kidney disease.
- Elite athletes or long-distance runners.
- Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
- Current use of laxatives or antidiarrheal medications.
- Use of other investigational products within 3 months of the screening visit.
- Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
- Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
- Current cancer treatment
- Currently pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Floridalead
- Lallemand Bio-Ingredientscollaborator
Study Sites (1)
Food Science and Human Nutrition Department, University of Florida
Gainesville, Florida, 32611, United States
Related Publications (1)
Moreno ML, Abbeele PVD, Baudot A, Tompkins TA, Taft DH, Yao R, Auger J, Colee J, Dahl WJ. Yeast mannans promote laxation and specifically modulate microbiota composition in older adults: An open-label pilot study. Nutr Res. 2025 Apr;136:15-27. doi: 10.1016/j.nutres.2025.02.004. Epub 2025 Feb 26.
PMID: 40117931DERIVED
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 3, 2023
First Posted
July 11, 2023
Study Start
August 1, 2023
Primary Completion
February 28, 2024
Study Completion (Estimated)
June 30, 2026
Last Updated
January 9, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share